$heff's $tation of $tocks & $olid DD

[north40000]

AMARIN[AMRN]: 2016 Investors Presentation:

http://files.shareholder.com/downloads/AMRN/3799831906x0x895423/386E7B25-0DE3-47EF-9B4F-AA402B99C6DF/AMRN_IR_Presentation_06072016.pdf

IMO, the slides speak for themselves. Those who understand the technology are well-invested. I have been taking the medication, Vascepa, off-label, since April 2013. I have only a familial history of CVEs from my father's side of the family, and Type 1 diabetes since 1956-7...my mother lived 'til age 92.

It is the other indications discussed in a substantial body of literature that interested me as well as my PCP, a former NIH research physician. The Dry-Eye Syndrome that I used to have disappeared in 3-4 days after beginning Vascepa. I placed a now slightly-outdated drop-box collection of that literature here. Here it is again:

https://dl.dropboxusercontent.com/u/57678878/Compilation%20of%20EPA%20Scientific%20Articles%20.pdf

Not to be forgotten are the 2 pieces of litigation Amarin engaged in with the FDA---Amarin won both in 2015. 1)Its ability to promote and market Vascepa, off label, to physicians and hospitals with truthful and not misleading advertising is now settled. 2)The NCE status of EPA and Vascepa is mentioned in the slides.


AMRN is our 2nd largest holding as an investment. 75% of our shares are currently profitable at current $2.13/share.